아미노글리코사이드 시장 기회, 성장 촉진 요인, 산업 동향 분석, 예측(2025-2034년)

The Global Aminoglycosides Market was valued at USD 1.9 billion in 2024 and is poised to grow at a CAGR of 4% from 2025 to 2034. Aminoglycosides are renowned for their robust efficacy against Gram-negative bacteria, making them indispensable in the treatment of various infectious diseases. Their widespread use in addressing conditions such as urinary tract infections, pneumonia, and sepsis underscores their vital role in modern healthcare. These antibiotics are a cornerstone in combating bacterial infections, particularly in scenarios where other treatments may falter. Their versatility, in line with the rising prevalence of antimicrobial resistance, has further cemented their demand in global markets.

Governments worldwide contribute significantly to the growth of the aminoglycosides market by incorporating these essential antibiotics into subsidized healthcare systems and national programs. This not only boosts accessibility but also ensures their availability for managing a broad spectrum of infectious diseases. In addition, the development and adoption of advanced formulations, such as inhalation solutions for intravenous administration, have expanded their application in treating bronchial diseases, amplifying the demand for aminoglycosides.

The market is segmented by product into neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, and other products. In 2024, gentamicin emerged as the leading segment with a market valuation of USD 541.6 million. The increasing prevalence of drug-resistant bacterial infections has heightened the reliance on potent antibiotics like gentamicin. As antimicrobial resistance continues to challenge the global healthcare landscape, gentamicin's efficacy has made it a preferred choice among healthcare professionals.

From an application standpoint, the aminoglycosides market is categorized into bacterial infections, tuberculosis, and other uses. Bacterial infections dominated the market, accounting for a 65.5% share in 2024. This category encompasses respiratory infections, skin and soft tissue infections, bone infections, and urinary tract infections. Hospital-acquired infections, such as pneumonia, urinary tract infections, and bloodstream infections, remain significant concerns, particularly those caused by Gram-negative pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae. These persistent challenges drive the demand for aminoglycosides as reliable therapeutic agents.

The United States aminoglycosides market was valued at USD 726.7 million in 2024, driven by a high incidence of bacterial infections and advanced healthcare infrastructure. Improved diagnostic capabilities have enabled targeted treatment strategies, fostering the precise and effective use of aminoglycosides. As bacterial infections continue to rise in prevalence, these factors are expected to sustain market growth momentum in the region over the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of bacterial infection
    • 3.2.1.2 Increasing surgical procedures
    • 3.2.1.3 Increasing awareness of antimicrobial resistance
    • 3.2.1.4 Technological advancement in combination therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative therapies
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Neomycin
• 5.3 Tobramycin
• 5.4 Gentamicin
• 5.5 Amikacin
• 5.6 Paromomycin
• 5.7 Streptomycin
• 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Bacterial infection
  • 6.2.1 Respiratory infections
  • 6.2.2 Skin and soft tissue infections
  • 6.2.3 Bone infections
  • 6.2.4 Urinary Tract Infections (UTIs)
• 6.3 Tuberculosis
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injectable
• 7.3 Oral
• 7.4 Topical
• 7.5 Ophthalmic

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Research and academic institutes
• 8.4 Homecare settings
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Aurobindo Pharma
• 10.2 Bausch Health Companies
• 10.3 Cipla
• 10.4 Fresenius Kabi
• 10.5 Kremoint Pharma (Bliss GVS Pharma)
• 10.6 Meiji Seika Pharma (Meiji Holdings)
• 10.7 Novartis
• 10.8 Perrigo Company
• 10.9 Pfizer
• 10.10 Sun Pharmaceutical Industries
• 10.11 Sanofi
• 10.12 Teva Pharmaceuticals